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Abstract
Background: The efficacy and safety of ketotifen eye drop treatment in allergic conjunctivitis (AC)
management is perfectly known by several studies, but the mechanism of action at the biochemical
levels is poorly understood so we decided to perform an open, uncontrolled study in order to
investigate the effect of the topical administration of ketotifen fumarate 0.05% on biochemical
markers of inflammation on conjunctival cells in patients with AC.
Methods: Nineteen patients with symptoms and signs of AC (itching, discharge, burning, redness,
increase in the watery discharge, swelling and follicles) and with a history of allergy were prescribed
with two daily instillation of one drop of eyewash ketotifen fumarate 0,05% in both eyes during
thirty days. They were studied by measuring clinical and immunologic parameters.
Results: Ketotifen fumarate treatment significantly reduced the total symptoms and signs score
for each patient as well as each symptoms and signs at all time points compared with day 0 (p <
0.0001 and p < 0.016, respectively). Although the percentage of HLA-DR+ epithelial cells
diminished only in 58% of patients, the numbers of CD29+ and eotaxin+ epithelial cells dropped
significantly in 68% and 73 % of them (p < 0.0062 and <0.0082, respectively) as a consequence of
the treatment. In 9 out of 19 patients a simultaneous decrease in the percentage of epithelial cells
positive for CD29 and eotaxin was observed.
Conclusion: Ketotifen besides the well-known effect in reducing signs and symptoms of AC
significantly diminished production of eotaxin and expression of CD29 by epithelial cells in patients
with seasonal AC.
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Background
Allergic conjunctivitis (AC) is an ocular surface inflamma-
tory disease that affects approximately 25% of the general
population [1–3] and has a significant impact on the so-
cial and economic aspects of life. It can appear alone or as-
sociated with other allergic diseases, especially allergic
rhinitis. AC is an immunopathological disease which the
number of mast cells in the substantia propria increase,
and also the epithelium becomes densely infiltrated [4,5].
Activation of mast cells by IgE bound-receptor crosslink-
ing by allergens promotes the release of several mediators
such as histamine, prostaglandins, leukotrienes, tryptase
and cytokines, all of them responsible for the symptoms
of AC and the inflammatory changes in conjunctival cells
[6–8].
Conjunctival epithelial cells (EC) play an important
proinflammatory role in chronic ocular allergic diseases,
the expression profile levels of different cellular adhesion
molecules and surface inflammatory antigens have been
reported in normal and altered human conjunctival epi-
thelium [9–11]. Recent results have demonstrated that ex-
pression of ICAM-1 may allow EC to recruit, retain and
locally concentrate leukocytes and the presence of HLA-
DR raises the question of conjunctival EC antigen presen-
tation [12].
Although the level of expression of CD29 (the common
chain of the beta 1 integrins) on normal conjunctival ECs
is already known [10], there is not information about
changes in its expression during AC. In addition, different
epithelial cytokines/chemokines, which are upregulated
actively, participate in allergic inflammation [13]. Among
those chemokines eotaxin not only play an important role
in eosinophilic recruiting and in damaging the tissue, but
also maintain this type of immune response [14].
AC can be treated with local anti-allergic agents such as
antihistamines, either alone or in combination with al-
pha-adrenergic agents and mast cell stabilizers [15–18].
Ketotifen fumarate is derived from cyproheptadine, a se-
rotonin and histamine antagonist [19]. The efficacy and
safety of this drug treatment in AC management is well
known [20,21] and its clinical use has also been widely
studied in relation to bronchial asthma where have been
demonstrated that ketotifen treatment significantly de-
creased EG2+ activated eosinophils, CD3+ and CD4+ T
cells in the bronchial mucosa and inhibit the expression
of E-selectin and ICAM-1 on vascular endothelial cells
[22–24].
The effects of different H1 antihistamines on ICAM-1 ex-
pression have been extensively studied [24–29], but since
there is not too much information about the effects of ke-
totifen on expression of CD29, HLA-DR and eotaxin on
conjunctival EC during AC, we performed an open, un-
controlled study on patients with AC to investigat the ef-
fect of this drug on clinical features and those markers of
inflammation.
Methods
Human subjects
Nineteen subjects (8 males and 11 females, between 6 and
63 years) with seasonal AC [30] and with a history of al-
lergy (allergic conjunctivitis, hay fever, asthmatic bronchi-
tis and dermatitis) who visited the Department of
Ophthalmology, Hospital Privado, Córdoba, Argentina,
during the spring season were evaluated. Those patients
were diagnosed as previously described [31] based on
positive allergen-skin prick test, IgE in tears, conjunctival
eosinophils, and symptoms and signs such as itching, dis-
charge, burning, redness, increase in the watery discharge,
swelling and presence of follicles. At day 0 they had nor-
mal levels of secretory IgA and lisozime and did neither
suffer from other eye disorder, nor had they experienced
any ophthalmologic treatment in the two previous weeks
to their enrollment. The use of contact lenses was sus-
pended for seventy two hours before and during the
whole study. All subjects gave informed consent and the
study was approved by the ethics committee of the Hospi-
tal Privado.
Each patient was prescribed with two daily instillations of
one drop of eyewash ketotifen fumarate 0,05% in both
eyes, during thirty days.
Ocular status assessment
Different symptoms (itching, tearing, burning, redness)
and signs (watery discharge increase, swelling, presence of
follicles) of allergic conjunctivitis were evaluated at their
enrollment (day zero) and at different times after starting
treatment (7, 15 and 30 days). Symptoms and signs were
classified in four stages: 0-Absent; 1-Mild; 2-Moderate and
3-Severe. The total symptoms and signs score (TSSS) for
each subject were obtained adding the values of each
symptoms and signs divided by the total number of them.
Immunological studies
Samples of conjunctival scrapings were collected from
both eyes of all patients treated on days 0 and 30 using a
disposable plastic scoop (Rhino probe™). The EC ob-
tained were suspended in 20% AB human serum – PBS
and incubated with anti-CD29 (beta chain of beta 1 in-
tegrin) RD1 (COULTER), anti-HLA-DR FITC (Becton
Dickinson), and anti-CD45 (Leukocyte common antigen)
PerCP (Becton Dickinson) monoclonal antibodies
(mAb), or isotopic antibody controls (Becton Dickinson)
for 45 min on ice. Another fraction of the EC was incubat-
ed with anti-eotaxin (CCL11) mAb (6H9, kindly provided
by LeukoSite Inc., Cambridge, MA) diluted with TritonBMC Ophthalmology 2003, 3 http://www.biomedcentral.com/1471-2415/3/2
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2%-PBS (Sigma) for 1 hour at 37°C, then it was incubated
with goat anti-mouse IgG FITC (SIGMA) antibody for 30
min on ice and finally with anti-CD45 PerCP (Becton
Dickinson) mAb, or isotopic antibody controls (Becton
Dickinson) for 45 min on ice. The samples were properly
washed and fixed with paraformaldehyde 1% and ana-
lyzed on a flow cytometer (Cytoron Absolute), equipped
with an argon laser emitting at 488 nm. Analytical gates
were set to discard cell debris and CD45+ cells. The
number of antigen-positive EC was then obtained from a
quadrant graphic paper representing mean fluorescence
intensities (MFI) on a 3-decade logarithmic amplifier. The
upper limit of intensity of fluorescence from the control
antibody was regarded as positivity threshold for the test-
ed antibodies. For each sample, 1.000–5.000 EC were an-
alyzed.
Statistical analysis
Variability of the parameters studied was analyzed with
Wilcoxon matched-pairs signed-rank test. For all tests, p ≤
0,05 was considered significant.
Results
After 7 days of treatment, 53% of patients showed im-
provements of their symptoms and signs (p < 0.0001).
With continued treatment through day 14, symptoms
control was achieved in 76% of patients (p < 0.0001).
Moreover, administration of 0,05% ketotifen eye drops
for thirty days significantly (p < 0.0001) reduced the TSSS
for each patient (Figure 1) between days 0 and 30.
Treatment with this drug has clinical effect on burning,
watery discharge, and swelling, particularly, at the end of
the treatment. Every other symptom were significantly re-
duced (p < 0.016) at any time of clinical evaluation (Fig-
ure 2).
Figure 1
Variation of total score of symptoms and signs for each patient with ketotifen treatment. The differences 
between time points were analyzed by Wilcoxon signed-rank test (*, p < 0.0001, day 0 vs 7, 15 and 30; and 7 vs 30; **, p < 
0.0002, day 7 vs 15; ***, p < 0.0008 day 15 vs 30).BMC Ophthalmology 2003, 3 http://www.biomedcentral.com/1471-2415/3/2
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The effect of the treatment was also studied on the expres-
sion of different molecules on CD45 negative cells (EC)
by FACS. It is worth to note that cells studied which were
obtained by conjunctival scraping never contain more
than 3 % of CD45 + cells (data not shown).
When the expression of HLA-DR, CD29 and eotaxin on
EC was evaluated after the treatment we found a drop in
the percentage of those positive EC in 58%, 68% and 73%
of patients, respectively. Although the variation in per-
centage of HLA-DR+ EC was not significant, the percent-
age of CD29+ and eotaxin + EC significantly decreased (p
< 0.0062 and <0.0082, respectively) at the end of the treat-
ment (Table 1). In 9/19 patients a simultaneous drop in
EC positive for CD29 and eotaxin was observed. Figure 3
shows a representative case from this group of patients.
We did not find any correlation between variations in
mean fluorescent intensity and percentage of positive EC
for these markers before and after the treatment.
Discussion
AC is a common, prevalent, and clinically significant IgE
mediate hypersensitivity response in which signs and
symptoms associated with the progression from early to
late phase reaction start four to eight hours after challenge
and persist up to 24 hours. The clinical reaction is accom-
panied by a significant recruitment of inflammatory cells
(mainly neutrophils) in tears 20 minutes after challenge,
and eosinophils and lymphocytes 6 to 24 hours after chal-
lenge [32]. In the chronic and more severe forms of AC,
other mechanisms and cells contribute to a more complex
clinical profile [33]. In addition, the mast cell is consid-
Figure 2
Variation of total score of symptoms and signs with ketotifen treatment. The differences between time points were 
analyzed by Wilcoxon signed-rank test (*, p < 0.016, day 0 vs 7, 15 and 30; day 7 vs 30, and day 15 vs 30; **, p < 0.031, day 7 vs 
15).BMC Ophthalmology 2003, 3 http://www.biomedcentral.com/1471-2415/3/2
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Figure 3
HLA-DR, CD29 and eotaxin expression by EC from patients with AC before and after the treatment with 
ketotifen fumarate 0.05%. Data show one representative case from nine patients who had a simultaneous drop in CD29+ 
and eotaxin+ EC.BMC Ophthalmology 2003, 3 http://www.biomedcentral.com/1471-2415/3/2
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ered to play a pivotal role in causing signs and symptoms
since Bacon AS et al found increased levels of histamine,
tryptase, PGD2, and leukotriene C4 in the tears of patients
with Seasonal Allergic Conjunctivitis after conjunctival al-
lergen challenge [34].
It is now becoming clear that EC may be viewed as active
participants in the regulation of inflammation and leuko-
cyte behavior. EC from a number of mucosal sites have
been shown to be capable of: 1) expressing adhesion mol-
ecules like ICAM-1 (CD54) or beta 1 integrin (CD29),
which are important for leukocyte emigration into tissue;
2) expressing MHC class II molecules and 3) synthesizing
and releasing prostaglandins and leukotrienes which at-
tract and activate leukocytes and 4) producing a variety of
pro-inflammatory cytokines and chemokines. The adhe-
sion molecules expressed on EC not only allow interac-
tions between cells and cells with matrix but also they
might be involved in intracellular signals [12,13,35–37].
Although we did not found significant variations in the
percentage of HLA-DR+ EC before and after treatment, the
majority of patients exhibited a significant decrease in the
percentage of CD29+ cells suggesting that the expression
of these molecules are controlled by different mecha-
nisms.
Eotaxin, a CC chemokine, is a potent and selective eosi-
nophil chemoattractant to the site of inflammation but
also plays an important role in damaging tissue by its ca-
pacity to induce the release of reactive oxygen species
[38,39]. It has been previously demonstrated that eotaxin
mRNA and protein are constitutively expressed by bron-
chial and nasal epithelium from normal individuals and
increased within the airways of asthmatic individuals, and
in nasal biopsy specimens from individuals with allergic
rhinitis. In addition eotaxin immunoreactivity was found
in macrophages, eosinophils, T cells, mast cells, and neu-
trophils, suggesting that this chemokine is an important
mediator in the physiological and pathological trafficking
of eosinophils [40,41].
It has been reported that in EC from normal conjunctival
biopsies there is a weak cytoplasmic expression of eotaxin
[13]. In our study we found a strong expression of eotaxin
on EC from patients with AC which decrease significantly
after treatment with ketotifen.
Current therapy of ocular allergic disease focuses on aller-
gen elimination, modulation of the immune system and
pharmacological inhibition of the chemical mediators in-
volved in the immune response. The most commonly
used therapeutic option is the pharmacological inhibition
of chemical mediators. Mast cells stabilizers and antihista-
Table 1: Percentage of positive EC before and after the treatment with ketotifen fumarate 0.05%.
Patients HLA-DR positive cells* CD29 positive cells* Eotaxin positive cells*
Day 0 Day 30 Day 0 Day 30 Day 0 Day 30
1 6 03 08 23 86 95 2
2 1 83 16 73 48 16 6
3 5 03 48 67 07 56 4
4 4 63 05 92 78 36 9
5 1 06 56 15 08 66 4
6 4 58 08 17 38 58 4
7 1 25 57 84 59 87 2
8 7 53 28 52 59 48 3
9 9 11 96 55 19 37 0
10 32 70 36 54 51 66
11 21 11 64 13 68 82
12 24 27 22 23 74 60
13 20 12 17 24 76 65
14 62 31 81 37 63 72
15 55 72 54 83 77 57
16 82 41 91 41 81 89
1 78 0 3 7 58 08 47 2
18 67 11 81 48 79 84
19 17 63 42 45 76 56
M e d i a 4 63 86 44 57 97 0
SD 26 23 22 19 11 10
* See Methods.BMC Ophthalmology 2003, 3 http://www.biomedcentral.com/1471-2415/3/2
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mines are two of the most commonly used group of ther-
apeutic agents; they stabilize the mast cell membranes by
preventing calcium influx across the mast cell mem-
branes, thereby preventing mast cell degranulation and
mediator release and the new antihistamines have been
demonstrated to be capable of affecting several phenome-
na of the allergic inflammation, including mediator re-
lease, cellular activation and adhesion molecule
expression [42,43]. Among these drugs, ketotifen fuma-
rate, attenuated the local allergic reaction in patients with
AC [20,21] and the efficacy and safety of this drug in AC
management has also been shown in human conjunctival
allergen challenge model [44,45].
Here, we corroborated the effectiveness of ketotifen fuma-
rate in decreasing the symptoms and signs of AC in the
majority of patients, but more importantly we showed
that this drug even though was not effected in reducing
the expression of HLA-DR on EC, it significantly decreased
the percentage of CD29+ and eotaxin+ EC.
The mechanism of action by which this drug produce this
effects are probably related to the decrease amounts of in-
flammatory cytokines/chemokines released by effector
cells at the conjunctival level. Clearly, additional studies
are needed to fully understand the complex mechanisms
of the anti-inflammatory effect of Ketotifen fumarate in
patients with AC.
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